Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T.
Sakata Y, et al. Among authors: otsuki t.
Lung Cancer. 2024 Feb;188:107450. doi: 10.1016/j.lungcan.2023.107450. Epub 2023 Dec 30.
Lung Cancer. 2024.
PMID: 38160082
No abstract available.